StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for LITS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.16 | $1.09 | -5.60% | 0.6M |
| 05-19 | $1.08 | $1.09 | +0.93% | 0.2M |
| 05-20 | $1.09 | $1.12 | +2.75% | 0.2M |
| 05-21 | $1.10 | $1.10 | +0.00% | 0.3M |
| 05-22 | $1.07 | $1.07 | +0.00% | 0.9M |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2018 2018-09-30 | Q3 2017 2017-09-30 |
|---|---|---|
Revenue | $488.00K | $283.00K |
Operating Income | $-10.03M | $-8.89M |
Net Income | $-14.54M | $-8.79M |
EPS (Diluted) | $-0.21 | $-0.24 |
Total Assets | $94.75M | $48.03M |
Total Liabilities | $54.99M | Not available |
Cash & Equivalents | $6.12M | $6.96M |
Free Cash Flow OCF − CapEx | Not available | Not available |
Shares Outstanding | 71.11M | 36.95M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.